Compare AI & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | CDNA |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2007 |
| Metric | AI | CDNA |
|---|---|---|
| Price | $8.90 | $28.82 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 6 |
| Target Price | $14.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 8.1M | 866.7K |
| Earning Date | 05-27-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $250,268,000.00 | $48,324,000.00 |
| Revenue This Year | N/A | $16.01 |
| Revenue Next Year | N/A | $11.31 |
| P/E Ratio | ★ N/A | $557.00 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $7.68 | $10.96 |
| 52 Week High | $30.11 | $28.42 |
| Indicator | AI | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 72.98 |
| Support Level | $8.01 | $14.59 |
| Resistance Level | $9.79 | N/A |
| Average True Range (ATR) | 0.69 | 1.38 |
| MACD | -0.28 | 0.44 |
| Stochastic Oscillator | 12.41 | 89.81 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.